Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 7 Disease activity and prognosis of spondyloarthritis].

Literature DB >> 25181975

[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 7 Disease activity and prognosis of spondyloarthritis].

U Kiltz¹, M Rudwaleit, J Sieper, D Krause, U Oberschelp, E Schneider, B Swoboda, H Böhm, J Braun.

Abstract

Entities: Disease

Mesh：

Year: 2014 PMID： 25181975 DOI： 10.1007/s00393-014-1432-x

Source DB: PubMed Journal: Z Rheumatol ISSN： 0340-1855 Impact factor: 1.372

Keyword Cloud
References

× No keyword cloud information.

20 in total

1. High intraindividual week-to-week variability in BASDAI and BASFI values: are several evaluations needed before starting or stopping TNFalpha antagonist therapy for spondyloarthropathies?

Authors: Jean-Marie Berthelot; Laetitia Tortellier; Delphine Lavy-Bregeon; Benoît Le Goff; Yves Maugars
Journal: Joint Bone Spine Date: 2008-01-14 Impact factor: 4.929

2. Risk factors for functional limitations in patients with long-standing ankylosing spondylitis.

Authors: Michael M Ward; Michael H Weisman; John C Davis; John D Reveille
Journal: Arthritis Rheum Date: 2005-10-15

3. The outcome of ankylosing spondylitis: a study of 100 patients.

Authors: J T Gran; J F Skomsvoll
Journal: Br J Rheumatol Date: 1997-07

4. Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis.

Authors: S Z Aydin; M Can; P Atagunduz; H Direskeneli
Journal: Clin Exp Rheumatol Date: 2010-10-22 Impact factor: 4.473

5. Discrimination ability of ASDAS estimating disease activity status in patients with ankylosing spondylitis.

Authors: Kemal Nas; Kadir Yildirim; Remzi Cevik; Saliha Karatay; Akin Erdal; Ozlem Baysal; Zuhal Altay; Ayhan Kamanli; Yuksel Ersoy; Arzu Kaya; Bekir Durmus; Ozge Ardicoglu; Ibrahim Tekeoglu; Mahir Ugur; Aysegul Jale Sarac; Kazim Senel; Ali Gur; Salih Ozgocmen
Journal: Int J Rheum Dis Date: 2010-08 Impact factor: 2.454

6. Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: a prospective study.

Authors: Stephan Pavy; Sinead Brophy; Andrei Calin
Journal: J Rheumatol Date: 2005-01 Impact factor: 4.666

[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 7 Disease activity and prognosis of spondyloarthritis].

1. High intraindividual week-to-week variability in BASDAI and BASFI values: are several evaluations needed before starting or stopping TNFalpha antagonist therapy for spondyloarthropathies?

2. Risk factors for functional limitations in patients with long-standing ankylosing spondylitis.

3. The outcome of ankylosing spondylitis: a study of 100 patients.

4. Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis.

5. Discrimination ability of ASDAS estimating disease activity status in patients with ankylosing spondylitis.

6. Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: a prospective study.

7. Smoking and outcome in ankylosing spondylitis.

8. [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany].

9. Predictors of longterm outcome in ankylosing spondylitis.

10. The natural history of ankylosing spondylitis as defined by radiological progression.